THE INTRATUMORAL IMMUNOTHERAPY COMPANY - Trademark Details
Status: 641 - Non-Final Action - Mailed
Image for trademark with serial number 90491212
Serial Number
90491212
Word Mark
THE INTRATUMORAL IMMUNOTHERAPY COMPANY
Status
641 - Non-Final Action - Mailed
Status Date
2021-08-17
Filing Date
2021-01-27
Mark Drawing
4000 - Standard character mark Typeset
Attorney Name
Jessica L. Rothstein
Law Office Assigned Location Code
L40
Employee Name
MARTIN, CHRISTINE C
Statements
Goods and Services
Research and development in the pharmaceutical and biotechnology fields
Classification Information
International Class
042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software; legal services. - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software; legal services.
US Class Codes
100, 101
Class Status Code
6 - Active
Class Status Date
2021-04-28
Primary Code
042
First Use Anywhere Date
2020-11-01
First Use In Commerce Date
2020-11-01
Current Trademark Owners
Party Name
Syncromune, Inc.
Party Type
10 - Original Applicant
Legal Entity Type
03 - Corporation
Address
Please log in with your Justia account to see this address.
Correspondences
Name
Jessica L. Rothstein
Address
Please log in with your Justia account to see this address.
Trademark Events
Event DateEvent Description
2021-01-30NEW APPLICATION ENTERED IN TRAM
2021-04-28NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM
2021-08-16ASSIGNED TO EXAMINER
2021-08-17NON-FINAL ACTION WRITTEN
2021-08-17NON-FINAL ACTION E-MAILED
2021-08-17NOTIFICATION OF NON-FINAL ACTION E-MAILED
2022-01-29TEAS CHANGE OF OWNER ADDRESS RECEIVED
2022-01-29TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
2022-01-29ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
2022-01-29TEAS CHANGE OF CORRESPONDENCE RECEIVED
2022-01-29APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
2022-02-01ASSIGNED TO EXAMINER